.svg)
BLOG
The Latest on Solid IO
Solid IO and Ymmunobio collaborate on cancer drug testing
We're excited to announce a new research collaboration with Ymmunobio, a Swiss oncology biotech company developing first-in-class targeted therapies for solid tumors. Through this collaboration, Ymmunobio will use Solid IO's ex vivo tumor-on-chip platform to evaluate the response of patient-derived tumor tissue to an investigational cancer therapy.
Strategic Funding: More than just capital
Solid IO closed its first equity funding round immediately after spinning out from the University of Helsinki.
Solid IO Raises € 800 000 to Eliminate the Guesswork in Cancer Care
The Funding will Support Next-Generation Tumor Modeling for Precision Oncology & Immunotherapy Advancements
Organ-on-Chip: A Breakthrough in Biomedical Research
For decades, scientists have relied on cell cultures and animal models to study diseases and test new drugs. Now, organ-on-chip (OoC) technology is set to change that.
Solid IO Launches on World Cancer Day: A New Era in Precision Oncology
On World Cancer Day, Solid IO officially launches, marking the beginning of a mission to end guesswork in cancer care.
Breaking New Ground in Personalized Cancer Care
Solid IO’s first publication showcases advances in tumor-on-chip technology
Shape the future of cancer care
Join SolidIO in transforming cancer care with groundbreaking organ-on-chip technology. We’re calling on researchers, clinicians, and investors to partner with us in advancing precision medicine, accelerating innovation, and expanding global access to personalized oncology. Together, we can bring clarity and better outcomes to cancer care worldwide.